These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 19198107)
1. [New era has begun since the approval of thrombolytic therapy for acute ischemic stroke in Japan]. Minematsu K Rinsho Shinkeigaku; 2008 Nov; 48(11):889-91. PubMed ID: 19198107 [TBL] [Abstract][Full Text] [Related]
2. [Prospects of thrombolytic therapy for acute ischemic stroke]. Nakashima T; Minematsu K Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399 [TBL] [Abstract][Full Text] [Related]
3. [Intravenous rt-PA therapy for acute ischemic stroke: efficacy and limitations]. Toyoda K Rinsho Shinkeigaku; 2009 Nov; 49(11):801-3. PubMed ID: 20030214 [TBL] [Abstract][Full Text] [Related]
4. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. Minematsu K; Toyoda K; Hirano T; Kimura K; Kondo R; Mori E; Nakagawara J; Sakai N; Shiokawa Y; Tanahashi N; Yasaka M; Katayama Y; Miyamoto S; Ogawa A; Sasaki M; Suga S; Yamaguchi T; J Stroke Cerebrovasc Dis; 2013 Jul; 22(5):571-600. PubMed ID: 23727456 [TBL] [Abstract][Full Text] [Related]
5. [Current and future aspects of intravenous thrombolysis for acute stroke]. Toyoda K Brain Nerve; 2013 Jul; 65(7):753-60. PubMed ID: 23832978 [TBL] [Abstract][Full Text] [Related]
6. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Nakagawara J; Minematsu K; Okada Y; Tanahashi N; Nagahiro S; Mori E; Shinohara Y; Yamaguchi T; Stroke; 2010 Sep; 41(9):1984-9. PubMed ID: 20651262 [TBL] [Abstract][Full Text] [Related]
7. Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study. Sato S; Uehara T; Toyoda K; Yasui N; Hata T; Ueda T; Okada Y; Toyota A; Hasegawa Y; Naritomi H; Minematsu K; Stroke; 2009 Jan; 40(1):30-4. PubMed ID: 18948604 [TBL] [Abstract][Full Text] [Related]
8. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y; Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187 [TBL] [Abstract][Full Text] [Related]
9. [The future perspective of acute thrombolytic therapy for acute ischemic stroke]. Matsuki T; Toyoda K Nihon Rinsho; 2016 Apr; 74(4):613-20. PubMed ID: 27333749 [TBL] [Abstract][Full Text] [Related]
10. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study. Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M; J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972 [TBL] [Abstract][Full Text] [Related]
11. Hyperacute stroke therapy with tissue plasminogen activator. Alberts MJ Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041 [TBL] [Abstract][Full Text] [Related]
12. Role of tissue plasminogen activator in acute ischemic stroke. Hatcher MA; Starr JA Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027 [TBL] [Abstract][Full Text] [Related]
13. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT). Mori E; Minematsu K; Nakagawara J; Yamaguchi T; J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535 [TBL] [Abstract][Full Text] [Related]
19. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies. Külkens S; Hacke W Expert Rev Neurother; 2007 Jul; 7(7):783-8. PubMed ID: 17610385 [TBL] [Abstract][Full Text] [Related]